Strivectin blazed an early trail in the cosmeceutical frontier with its results-driven skin-care platform, but claims for at least two of its offerings identify the products as unapproved drugs, according to an FDA warning letter.
Posted to FDA’s website March 9, the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?